Research hub · 8 articles

Peptide Regulation & 503A

Regulation is the part of peptide supply that changes faster than the chemistry. The same molecule can be a lawful compounding ingredient in one jurisdiction, an unapproved drug in a second, and a scheduled substance in a third, and the status can shift on the publication of a single list. For a laboratory buyer, that means the paperwork around a compound is as much a part of its identity as the certificate of analysis.

The articles in this cluster trace the mechanics rather than the politics. One explains what section 503A of the Food, Drug and Cosmetic Act allows a licensed compounding pharmacy to do with bulk substances, and why the FDA's bulk-substance category lists matter more than any individual enforcement action. Another follows the sequence of import alerts and market withdrawals that reshaped research-peptide availability through 2025 and into 2026. A third walks through a certificate of analysis in detail, because the COA is where regulatory claims and analytical reality meet, and the two often diverge. Read them together: the timeline makes more sense once the 503A framework is clear, and the COA piece explains what documentation survives a compliance question.

Dates matter here more than in any other hub. The timeline piece is written to be read against its publication date, and an alert that was current in mid-2026 may have been superseded by the time you read it. Where a page states a regulatory fact it names the instrument — a bulk-substance list, an import alert, a guidance document — so the claim can be re-checked at the source rather than taken on our authority.

Articles in this hub

Related categories

Related tools

More hubs and compound references in the research journal; analytical documentation on the quality page; or request a quote.